Fig 1: Effect of biological drugs. Insulin resistance influence in the therapy response(A) ? DAS28 in insulin resistance RA patients compared with insulin sensitivity RA patients after six months of treatment with biologicals (n = 67).(B) HOMA-IR levels at baseline in responders and non-responder RA patients (n = 67).(C) Insulin levels at baseline in responder and non-responder RA patients (n = 67).(D) Glucose levels at baseline in responder and non-responder RA patients (n = 123).(E) Visfatin levels at baseline in responder and non-responder RA patients (n = 123).(F) Vaspin levels at baseline in responder and non-responder RA patients (n = 123).(G) Effect of anti-CD20 therapy on the ACPAs titers and the adipocytokine profile after six months of treatment (n = 56).(H) Effect of anti-TNF-a therapy on the ACPAs titers and the adipocytokine profile after six months of treatment (n = 45).(I) Effect of the anti-IL6R therapy on the ACPAs titers and the adipocytokine profile after six months of treatment (n = 22). DAS28: disease activity score 28; HOMA-IR: homeostatic model assessment-insulin resistance; IR: insulin resistance; IS: insulin sensitivity; ns: non-significant; ACPAs: anti-bodies to citrullinated protein antigens; Resp: responder; TNF-a: tumor necrosis factor alpha: IL: interleukin; IL-6R: interleukin 6 receptor; CD: cluster differentiation; ADIPOQ: adiponectin. Significance was determined by t-test or Mann–Whitney rank-sum test for unpaired groups. t-test or Wilcoxon matched-pairs signed rank test were used for paired groups. *Significant differences vs baseline, p < 0.05. **Significant differences vs baseline, p < 0.01. ***Significant differences vs baseline, p < 0.001. Data are represented as mean ± SEM.